ACTINIUM PHARMACEUTICALS INC (ATNM)
US00507W2061 - Common Stock
Taking everything into account, ATNM scores 2 out of 10 in our fundamental rating. ATNM was compared to 573 industry peers in the Biotechnology industry. Both the profitability and financial health of ATNM have multiple concerns. While showing a medium growth rate, ATNM is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year ATNM has reported negative net income.
ATNM had a negative operating cash flow in the past year.
In the past 5 years ATNM always reported negative net income.
ATNM had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -47.43%, ATNM perfoms like the industry average, outperforming 50.35% of the companies in the same industry.
ATNM's Return On Equity of -97.24% is in line compared to the rest of the industry. ATNM outperforms 45.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.43% | ||
| ROE | -97.24% | ||
| ROIC | N/A |
ROA(3y)-39.89%
ROA(5y)-68.16%
ROE(3y)-72.51%
ROE(5y)-128.35%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ATNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATNM has more shares outstanding
The number of shares outstanding for ATNM has been increased compared to 5 years ago.
Compared to 1 year ago, ATNM has a worse debt to assets ratio.
2.2 Solvency
ATNM has an Altman-Z score of -5.50. This is a bad value and indicates that ATNM is not financially healthy and even has some risk of bankruptcy.
ATNM's Altman-Z score of -5.50 is on the low side compared to the rest of the industry. ATNM is outperformed by 65.14% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ATNM is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, ATNM is in line with its industry, outperforming 51.06% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.5 |
ROIC/WACCN/A
WACC10.21%
2.3 Liquidity
A Current Ratio of 8.95 indicates that ATNM has no problem at all paying its short term obligations.
ATNM's Current ratio of 8.95 is fine compared to the rest of the industry. ATNM outperforms 76.94% of its industry peers.
A Quick Ratio of 8.95 indicates that ATNM has no problem at all paying its short term obligations.
ATNM has a better Quick ratio (8.95) than 76.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.95 | ||
| Quick Ratio | 8.95 |
3. Growth
3.1 Past
ATNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.48%, which is quite good.
Looking at the last year, ATNM shows a very strong growth in Revenue. The Revenue has grown by 80.00%.
EPS 1Y (TTM)16.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.48%
Revenue 1Y (TTM)80%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 34.35% on average over the next years. This is a very strong growth
ATNM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 359.61% yearly.
EPS Next Y26.94%
EPS Next 2Y25.07%
EPS Next 3Y10.6%
EPS Next 5Y34.35%
Revenue Next Year-100%
Revenue Next 2Y1330.12%
Revenue Next 3Y689.91%
Revenue Next 5Y359.61%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ATNM. In the last year negative earnings were reported.
Also next year ATNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.07%
EPS Next 3Y10.6%
5. Dividend
5.1 Amount
No dividends for ATNM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ACTINIUM PHARMACEUTICALS INC
NYSEARCA:ATNM (9/16/2024, 3:36:52 PM)
1.75
-0.11 (-5.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap54.51M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.43% | ||
| ROE | -97.24% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.95 | ||
| Quick Ratio | 8.95 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)16.48%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y26.94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)80%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y